German-based biocatalysis solution provider Enzymaster has recently completed a round-C fundraiser of more than $45 million.
The company says the funds will be used to facilitate further investments in scientific innovation, technologies and production capacity. According to Enzymaster, these advancements are needed to help organizations around the world leverage biocatalysis to decrease dependence on toxic, environmentally damaging, and often inefficient processes for chemical manufacturing.
“From the outset, our strategic plan has been to support target industries with a full range of solutions, from enzyme-engineering R&D to commercial-production of chemicals, for facilitating more efficient and sustainable manufacturing,” said Dr. Yong Koy Bong, Enzymaster’s chairman of the board of directors.
China's Yuanbio Venture Capital was the lead investor in the financing round, with participation from Bayland Capital, Puhua Capital, C&D Emerging Capital, Hansoh Investment, Carbonneutral Partnership and Probe Capital.
In addition to ongoing funding of R&D innovation, Enzymaster acquired Sanming Minhe Pharmaceutical Technology last November to meet growing production capacity demand.
